International Journal of Pharmacology and Pharmaceutical Sciences

Vol. 1, Issue 1, Part A (2019)

Lasmiditan: A new drug for acute migraine


Ardra PK, Kavya Prathap, Sherin M Saji, Irene Thomas, Ansa Mathew

In related to the increased risk of cardio vascular (CV) diseases associated with migraine, there is a interest in the development of a new drug in the treatment of acute migraine which selectively act on non-vascular targets. Existing treatments are limited due to contra indications, or patient avoidance of side effects. This analysis show that 5-HT1F agonist have shown improved results in the treatment of migraine head ache. Also indicated the safety and efficacy of oral lasmiditan, a selective serotonin 5-hydroxytryptamine 1F receptor agonist in the migraine treatment. Research suggests that lasmiditan lacks vasoconstrictive properties and may be a safe and effective treatment in patient’s refractory to the acute migraine medications compared to the currently used drugs for migraine.

Pages: 17-19  |  1933 Views  1159 Downloads

How to cite this article:
Ardra PK, Kavya Prathap, Sherin M Saji, Irene Thomas, Ansa Mathew. Lasmiditan: A new drug for acute migraine. Int. J. Pharmacol. Pharm. Sci. 2019;1(1):17-19. DOI: 10.33545/26647206.2019.v1.i1a.5